• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

JPMorgan Chinese Investment Trust plc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider JP Morgan Asset Management (UK) Ltd
Fund Summary To provide long term capital growth by investment in Greater China companies.
SEDOL code 0343501
ISIN GB0003435012
Fund code JMCLL
Managers Howard Wang, Rebecca Jiang, Shumin Huang, Emerson Yip
Manager Tenure 14 years
Morningstar Category China Equity
Fund Size Currently unavailable
Fund Type ETF / IT
Management Style Active
Total Expense Ratio (TER) 1.44%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £3.2268
Buy Price £3.2533
Price Date 12th November 2019
Yield Currently unavailable
Dividend Frequency Yearly
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 4th July 2016
Fund Status OPEN
Howard Wang, managing director, is a country specialist for Greater China equities and head of the Greater China Team within the Emerging Markets and Asia Pacific (EMAP) Equities Team. Based in Hong Kong, he leads the Greater China-dedicated portfolio management teams in Hong Kong and Taipei and serves as the primary advisor for the investment team at J.P. Morgan Asset Management(JPMAM) Shanghai-based joint venture China International Fund Management (CIFM). He joined the Firm in 2005 after eight years at Goldman Sachs, where he was managing director and head of the Taipei office as well as an executive director with Goldman equities principal strategies team in Hong Kong. He began his career with Lazard in 1995 as a financial analyst in mergers & acquisitions in New York. Howard obtained a B.A. summa cum laude in economics from Yale University, where he was elected vice president of Phi Beta Kappa.

3-year Mean Monthly Return: 1.374%

Annual Returns 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Fund Performance +19.35% -4.98% +36.36% +37.99% -6.96% +11.98% +16.50% +7.91% -20.41% +12.92%
Benchmark Performance
(China Equity)
+4.04% -0.73% +22.51% +30.80% +4.86%
Time Period Cumulative Benchmark Performance
(China Equity)
Fund Compared to Benchmark
1 day 0.46% +15.91% -15.44%
1 week 0.46% +2.54% -2.07%
1 month 6.39% +2.95% +3.44%
3 months 12.67% +3.93% +8.75%
6 months 10.94% +14.69% -3.75%
1 year 39.46% +9.51% +29.94%
3 years 18.20% +10.31% +7.89%
5 years 14.46% +6.65% +7.81%
10 years 9.91% +8.73% +1.18%
YTD 42.32% -0.84% +43.16%
Since inception 5.59% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Alibaba Group Holding Ltd ADR CHN 11.08%
Scotia Bank Usd Stl CAN 10.81%
Tencent Holdings Ltd CHN 9.82%
Ping An Insurance (Group) Co. of China Ltd Class H CHN 6.28%
Pinduoduo Inc ADR CHN 3.59%
WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S USA 3.31%
Jiangsu Hengrui Medicine Co Ltd CHN 2.54%
ENN Energy Holdings Ltd CHN 2.52%
Sunny Optical Technology (Group) Co Ltd CHN 2.44%
Kweichow Moutai Co Ltd CHN 2.32%
Dividend Date Per share amount Reinvestment Price
13th December 2018 0.0350 £2.4600
14th December 2017 0.0160 £3.0125
15th December 2016 0.0160 £1.9300
10th December 2015 0.0180 £1.6300
11th December 2014 0.0160 £1.7500
11th December 2013 0.0160 £1.5625